Table 1.
Patient demographics and tumor characteristics
| Characteristic | ypT0N0 (n = 111) | Residual disease (n = 469) | P-value |
|---|---|---|---|
| Age (yr) | 62.00 (34–82) | 60.00 (27–81) | 0.071 |
| Sex | 0.114 | ||
| Male | 66 (59.5) | 316 (67.4) | |
| Female | 45 (40.5) | 153 (32.6) | |
| Body mass index (kg/m2) | 23.36 (16.98–29.15) | 22.86 (16.14–33.89) | 0.107 |
| ASA PS classification | 0.787 | ||
| I | 48 (43.2) | 193 (41.2) | |
| II | 60 (54.1) | 266 (56.7) | |
| III | 3 (2.7) | 10 (2.1) | |
| Diabetes mellitus | 0.983 | ||
| No | 96 (86.5) | 408 (87.0) | |
| Mild | 15 (13.5) | 59 (12.6) | |
| Severe | 0 (0) | 2 (0.4) | |
| Hypertension | 0.695 | ||
| No | 76 (68.5) | 330 (70.4) | |
| Yes | 35 (31.5) | 139 (29.6) | |
| Heart disease | 0.561 | ||
| No | 106 (95.5) | 454 (96.8) | |
| Yes | 5 (4.5) | 15 (3.2) | |
| Pulmonary disease | 0.239 | ||
| No | 108 (97.3) | 442 (94.2) | |
| Yes | 3 (2.7) | 27 (5.8) | |
| Liver disease | 1.000 | ||
| No | 108 (97.3) | 455 (97.0) | |
| Yes | 3 (2.7) | 14 (3.0) | |
| Clinical T classificationa | <0.001 | ||
| cT1 | 2 (1.8) | 1 (0.2) | |
| cT2 | 23 (20.9) | 55 (11.8) | |
| cT3 | 82 (74.5) | 361 (77.3) | |
| cT4 | 3 (2.7) | 50 (10.7) | |
| Tumor location from the anal verge (cm) | 0.995 | ||
| <4 | 28 (25.2) | 123 (26.2) | |
| 4–8 | 58 (52.3) | 235 (50.1) | |
| 8–12 | 23 (20.7) | 103 (22.0) | |
| ≥12 | 2 (1.8) | 8 (1.7) | |
| Pretreatment CEA (ng/mL)b | 2.0 (0–250) | 2.5 (0–336) | 0.010 |
| Post-CRT CEA (ng/mL)c | 1.6 (0–7) | 1.6 (0–45) | 0.947 |
| Change in CEA (mg/mL)d | 0 (–2 to 247) | 1.0 (–2 to 326) | 0.136 |
| Adjuvant chemotherapye | <0.001 | ||
| Yes | 70 (63.1) | 389 (83.1) | |
| No | 41 (36.9) | 79 (16.9) |
Values are presented as median (range) or number (%).
ASA PS, American Society of Anesthesiologists physical status; CEA, carcinoembryonic antigen; CRT, chemoradiotherapy.
a
Clinical T classification was not available in 1 patient with ypT0N0, and 2 patients with residual disease.
b
Data were available for 101 patients with ypT0N0, and 430 patients with residual disease.
c
Data were available for 107 patients with ypT0N0, and 437 patients with residual disease.
d
Data were available for 98 patients with ypT0N0, and 400 patients with residual disease.
e
Data were not available for one patient with residual disease.